TrialCNS oncology2016

A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.

Yazmin Odia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.